<DOC>
	<DOCNO>NCT02576626</DOCNO>
	<brief_summary>Rationale : Inhaled bronchodilator , beta-2-agonist anticholinergic combination , deliver several type device : dry powder ( DPI ) , pressurize meter dose inhaler ( pMDI ) , wet nebulizer . Wet nebulization available short-acting bronchodilator , cumbersome , , importantly , never scientifically proven efficacious delivery two method . Yet many patient happy wet nebulization many clinic administration method prevail . The investigator believe combine long-acting bronchodilator , efficacious combine short act bronchodilator per nebulizer . Objective : To test hypothesis : The combination two long-acting bronchodilator indacaterol glycopyrronium dry powder inhalation confers superior improvement compare nebulisation ipratropium/salbutamol , administer single dose patient stable state chronic obstructive pulmonary disease ( COPD ) . Study design : Investigator initiate , randomise , active control , cross-over double-blind ( therefore double-dummy ) , study compare effect single dose indacaterol/glycopyrronium 110/50 Breezhaler® versus single dose ipratropium/salbutamol nebulisation patient COPD stable state Study population : Patients visit outpatient clinic general practitioner ( GP ) practice COPD GOLD stage A-D , ( FEV1 ) post-bronchodilator FEV1/ force vital capacity ( FVC ) &lt; 70 % ; post-br FEV1 &lt; 80 % pred . Intervention The investigator compare effect single dose indacaterol/glycopyrronium 110/50 Breezhaler® versus single dose ipratropium/salbutamol nebulisation patient COPD stable state Main study parameters/endpoints : Area curve ( AUC ) 0 6 hour FEV1 indacaterol glycopyrronium , compare nebulisation ipratropium/salbutamol Nature extent burden risk associate participation , benefit group relatedness : This study specific benefit participate patient . The study also major risk . Minor risk participant single dosis throat irritation , cough , headache dizziness , sinus tachycardia . The combination treatments β2-agonist bronchodilator anticholinergic bronchodilator use daily practice many year many country often prescribed COPD . Both indacaterol/glycopyrronium ipratropium/salbutamol approve COPD treatment Netherlands</brief_summary>
	<brief_title>Single Dose Ultibro Breezhaler Sd-DPI Versus Ipratropium/Salbutamol Nebulizer COPD</brief_title>
	<detailed_description />
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>1 . COPD , postbronchodilator FEV1/FVC &lt; 70 % ; postbr FEV1 &lt; 80 % pred 2 . Active mastery Dutch 3 . Written inform consent 4 . At least 40 year old 5 . Participants must able understand complete protocol requirement , Instructions , questionnaires provide Dutch 1 . Non invasive ventilation 2 . Saturation pulse oxymetry &lt; 88 % 3 . Documented history asthma 4 . Instable cardiac disease within 6 month . 5 . Known long correct QT interval ( QTC ) syndrome 6 . Known estimated Glomerular Filtration Rate ( EGFR ) ( &lt; 30 ml/min *1,73m2 7 . Exacerbations COPD change medication COPD last 6 week prior inclusion 8 . Allergic reaction intolerance substance use one product atropine atropine derive substance 9 . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Nebulizer</keyword>
	<keyword>DPI</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>ipratropium</keyword>
	<keyword>glycopyrronium</keyword>
	<keyword>salbutamol</keyword>
	<keyword>Breezhaler</keyword>
	<keyword>Nebuliser</keyword>
	<keyword>Hyperinflation</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>SABA</keyword>
	<keyword>short-acting muscarinic antagonist ( SAMA )</keyword>
	<keyword>long-acting beta2-agonist ( LABA )</keyword>
	<keyword>LAMA</keyword>
	<keyword>FEV1</keyword>
</DOC>